Barbara Klencke
CIK 1647647 · Chief Medical Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$652.8K
Companies
6
Total Filings
35
Lifetime Open-Market Net
$322.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XNCR | Director | 29,974 | $19.97 | $598.6K | $0 | 4 | 2026-07-08 |
| TCRX | Director | 70,000 | $0.77 | $54.2K | $108.0K | 8 | 2026-05-22 |
| ALXO | Chief Medical Officer | — | $1.99 | — | $0 | 4 | 2026-04-17 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Director | — | $0.00 | — | $0 | 6 | 2024-06-13 |
| Sierra Oncology, Inc. (SRRA) Delisted | Chief Medical Officer | 0 | $54.99 | $0 | $214.1K | 11 | 2022-07-01 |
| Sierra Oncology, Inc. (DNAI) Delisted | Chief Development Officer | — | — | — | $0 | 2 | 2016-10-04 |
Recent Filings · Page 2 of 4
35 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-17 | XNCR | Grant (A) | +5,986 | $0 | EDGAR |
| 2024-06-14 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-21 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-18 | TCRX | Buy (P) | +5,000 | $25.4K | EDGAR |
| 2023-09-19 | XNCR | Grant (A) | — | $0 | EDGAR |
| 2023-06-22 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-15 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2023-04-10 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2023-01-24 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.